Sionna Therapeutics (NASDAQ:SION) Upgraded to “Hold” at Wall Street Zen

Sionna Therapeutics (NASDAQ:SION) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Sionna Therapeutics Price Performance

Shares of Sionna Therapeutics stock opened at $20.82 on Friday. Sionna Therapeutics has a 52-week low of $7.26 and a 52-week high of $25.19. The firm’s 50-day moving average price is $18.06.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.27.

Insider Buying and Selling at Sionna Therapeutics

In related news, major shareholder Tpg Gp A, Llc acquired 60,000 shares of the business’s stock in a transaction that occurred on Friday, June 27th. The shares were acquired at an average cost of $15.84 per share, with a total value of $950,400.00. Following the purchase, the insider owned 6,744,962 shares of the company’s stock, valued at approximately $106,840,198.08. The trade was a 0.90% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. RA Capital Management L.P. bought a new stake in shares of Sionna Therapeutics during the first quarter valued at approximately $109,258,000. TPG GP A LLC bought a new stake in shares of Sionna Therapeutics during the first quarter valued at approximately $69,925,000. Atlas Venture Life Science Advisors LLC bought a new stake in shares of Sionna Therapeutics during the first quarter valued at approximately $38,639,000. Braidwell LP bought a new stake in shares of Sionna Therapeutics during the second quarter valued at approximately $18,770,000. Finally, Jennison Associates LLC bought a new stake in shares of Sionna Therapeutics during the first quarter valued at approximately $8,995,000.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.